Physician profile
Kyle R Head
NPI 1386970895
$1,028.73
in general payments reported to CMS, 2019-2025
14 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $221 · 2021: $60.17 · 2022: $37.79 · 2024: $215 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360 · Entertainment: $51.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.27 |
| Entertainment | $51.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $247.53 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $184.50 | 2024-2025 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.42 | 2019-2020 | |
| Glaukos Corporation | $100.00 | 2020 | |
| Shire North American Group INC | $88.55 | 2019 | |
| Optos, INC. | $51.10 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $44.45 | 2025 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $38.83 | 2019 | |
| Sight Sciences, INC. | $29.67 | 2020-2022 | |
| Alcon Vision LLC | $27.55 | 2019-2020 | |
| Dompe US, INC. | $26.72 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $19.54 | 2025 | Tyrvaya |
| Lkc Technologies, INC. | $19.05 | 2024 | |
| Eyevance Pharmaceuticals LLC | $16.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.